KR20260020212A - 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법 - Google Patents

라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법

Info

Publication number
KR20260020212A
KR20260020212A KR1020267001774A KR20267001774A KR20260020212A KR 20260020212 A KR20260020212 A KR 20260020212A KR 1020267001774 A KR1020267001774 A KR 1020267001774A KR 20267001774 A KR20267001774 A KR 20267001774A KR 20260020212 A KR20260020212 A KR 20260020212A
Authority
KR
South Korea
Prior art keywords
cell proliferation
reducing cell
larinepaq
enhancers
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020267001774A
Other languages
English (en)
Korean (ko)
Inventor
루시 에이치. 클래프
도미니크 피. 비한
존 더블유. 아담스
Original Assignee
아레나 파마슈티칼스, 인크.
루시 에이치. 클래프
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아레나 파마슈티칼스, 인크., 루시 에이치. 클래프 filed Critical 아레나 파마슈티칼스, 인크.
Publication of KR20260020212A publication Critical patent/KR20260020212A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020267001774A 2016-11-10 2017-11-10 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법 Pending KR20260020212A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662420515P 2016-11-10 2016-11-10
US62/420,515 2016-11-10
US201762530533P 2017-07-10 2017-07-10
US62/530,533 2017-07-10
KR1020247014676A KR102916884B1 (ko) 2016-11-10 2017-11-10 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법
PCT/US2017/061116 WO2018089804A1 (en) 2016-11-10 2017-11-10 Methods of treating pah with combinations of ralinepag and other agents

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020247014676A Division KR102916884B1 (ko) 2016-11-10 2017-11-10 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법

Publications (1)

Publication Number Publication Date
KR20260020212A true KR20260020212A (ko) 2026-02-10

Family

ID=60451197

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020267001774A Pending KR20260020212A (ko) 2016-11-10 2017-11-10 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법
KR1020237003653A Abandoned KR20230021186A (ko) 2016-11-10 2017-11-10 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법
KR1020247014676A Active KR102916884B1 (ko) 2016-11-10 2017-11-10 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법
KR1020197016623A Abandoned KR20200015439A (ko) 2016-11-10 2017-11-10 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020237003653A Abandoned KR20230021186A (ko) 2016-11-10 2017-11-10 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법
KR1020247014676A Active KR102916884B1 (ko) 2016-11-10 2017-11-10 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법
KR1020197016623A Abandoned KR20200015439A (ko) 2016-11-10 2017-11-10 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법

Country Status (11)

Country Link
US (2) US12377067B2 (https=)
EP (2) EP3538154B1 (https=)
JP (3) JP2019533713A (https=)
KR (4) KR20260020212A (https=)
CN (2) CN119367341A (https=)
AU (3) AU2017357759A1 (https=)
CA (1) CA3043283A1 (https=)
ES (1) ES3052035T3 (https=)
IL (2) IL266518B1 (https=)
MA (1) MA46750A (https=)
WO (1) WO2018089804A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12377067B2 (en) 2016-11-10 2025-08-05 Arena Pharmaceuticals, Inc. Methods of treating PAH with combinations of ralinepag and other agents
IL268997B2 (en) 2017-03-01 2023-09-01 Arena Pharm Inc Preparations containing pgi2 receptor agonists and processes for their preparation
EP3796902A1 (en) * 2018-05-16 2021-03-31 Arena Pharmaceuticals, Inc. Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
CN108721296B (zh) * 2018-07-03 2019-04-05 中国人民解放军总医院 一种化合物在治疗或预防高原病中的用途
WO2020048299A1 (zh) * 2018-09-06 2020-03-12 广东东阳光药业有限公司 药物共晶体及其制备方法
PT3897646T (pt) 2018-12-21 2024-07-08 Actelion Pharmaceuticals Ltd Macitentano para tratamento de hipertensão arterial pulmonar
TW202042818A (zh) * 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
WO2023154705A1 (en) * 2022-02-08 2023-08-17 United Therapeutics Corporation Treprostinil iloprost combination therapy
WO2023158634A1 (en) 2022-02-15 2023-08-24 United Therapeutics Corporation Crystalline prostacyclin (ip) receptor agonist and uses thereof
US20250282716A1 (en) 2024-03-11 2025-09-11 United Therapeutics Corporation Methods of making ip-receptor agonists
CN121714543A (zh) * 2024-09-23 2026-03-24 上海欣药智能科技有限公司 一种可吸入的含可溶性鸟苷酸环化酶受体激动剂的药物组合物及其用途
US12582629B1 (en) * 2025-10-23 2026-03-24 Innovate Therapeutics Llc Extended-release pharmaceutical compositions of Ralinepag

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2085844A1 (en) 1991-12-27 1993-06-28 Nobuyuki Hamanaka Fused benzeneoxyacetic acid derivatives
GB9908934D0 (en) 1999-04-19 1999-06-16 Rolic Ag Liquid crystalline compounds
US20040048844A1 (en) 1999-10-20 2004-03-11 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
WO2002055484A1 (en) 2001-01-12 2002-07-18 Takeda Chemical Industries, Ltd. Biaryl compound, process for producing the same, and agent
WO2003007888A2 (en) 2001-07-20 2003-01-30 Adipogenix, Inc. Fat accumulation-modulating compounds
CN101284773A (zh) 2001-08-09 2008-10-15 小野药品工业株式会社 羧酸衍生物及以它为活性成分的药剂
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
TWI293715B (en) 2002-10-10 2008-02-21 Sipix Imaging Inc A method for inducing or enhancing the threshold of an electrophoretic display, an electrophoretic fluid and an electrophoretic display
RU2351590C2 (ru) 2003-02-10 2009-04-10 Вертекс Фармасьютикалз Инкорпорейтед Способ получения диариламина
GB0325291D0 (en) * 2003-10-29 2003-12-03 Pfizer Ltd Novel combination
JP2008510726A (ja) 2004-08-20 2008-04-10 エントレメッド インコーポレイテッド プロテイナーゼ活性化受容体アンタゴニストを含む組成物および方法
WO2007051255A1 (en) 2005-11-04 2007-05-10 The University Of Sydney Process for the preparation of compounds containing an azacyclic ring system
US20080075692A1 (en) 2006-05-09 2008-03-27 Perrine Susan P Methods for treating blood disorders
WO2009117095A1 (en) 2008-03-18 2009-09-24 Arena Pharmaceuticals, Inc. Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
US20110224262A1 (en) 2008-11-26 2011-09-15 Arena Pharmaceuticals, Inc. Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
ES2548882T3 (es) 2008-12-08 2015-10-21 Arena Pharmaceuticals, Inc. Moduladores del receptor de prostaciclina (PGl2) útiles para el tratamiento de trastornos relacionados con los mismos
WO2011037613A1 (en) * 2009-09-23 2011-03-31 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of pgi2 receptor agonists
US9388154B2 (en) * 2011-09-12 2016-07-12 Lund Biotechnology PBC Process for preparing synthetic prostacyclins
AU2013351934B2 (en) * 2012-11-30 2018-03-29 Insmed Incorporated Prostacylin compositions and methods for using the same
US10537546B2 (en) * 2014-10-23 2020-01-21 Arena Pharmaceuticals, Inc. Method of treating conditions related to the PGI2 receptor
CN107427698A (zh) * 2015-01-13 2017-12-01 维瓦斯公司 肺高血压的组合疗法
US12377067B2 (en) 2016-11-10 2025-08-05 Arena Pharmaceuticals, Inc. Methods of treating PAH with combinations of ralinepag and other agents

Also Published As

Publication number Publication date
JP2025131627A (ja) 2025-09-09
KR20240068077A (ko) 2024-05-17
JP2023029865A (ja) 2023-03-07
EP4681708A2 (en) 2026-01-21
AU2023263497A1 (en) 2023-11-30
AU2023263497C1 (en) 2026-01-22
WO2018089804A1 (en) 2018-05-17
ES3052035T3 (en) 2025-12-30
EP4681708A3 (en) 2026-03-18
US12377067B2 (en) 2025-08-05
EP3538154A1 (en) 2019-09-18
WO2018089804A9 (en) 2018-06-21
CN110691612B (zh) 2024-11-08
US20190321328A1 (en) 2019-10-24
CN119367341A (zh) 2025-01-28
KR20200015439A (ko) 2020-02-12
CA3043283A1 (en) 2018-05-17
EP3538154B1 (en) 2025-09-03
IL266518B1 (en) 2026-01-01
KR20230021186A (ko) 2023-02-13
IL323354A (en) 2025-11-01
JP2019533713A (ja) 2019-11-21
IL266518A (en) 2019-07-31
CN110691612A (zh) 2020-01-14
US20260014114A1 (en) 2026-01-15
AU2025283444A1 (en) 2026-01-15
MA46750A (fr) 2019-09-18
AU2017357759A1 (en) 2019-06-06
KR102916884B1 (ko) 2026-01-22
AU2023263497B2 (en) 2025-09-18

Similar Documents

Publication Publication Date Title
KR102916884B1 (ko) 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법
O'callaghan et al. Treatment of pulmonary arterial hypertension with targeted therapies
Grassi et al. Lercanidipine in the management of hypertension: an update
Frampton et al. Aliskiren: a review of its use in the management of hypertension
KR20070102544A (ko) 유기 화합물의 조합물
Galiè et al. Emerging medical therapies for pulmonary arterial hypertension
Siddiqui et al. Ranolazine: a review of its use in chronic stable angina pectoris
CA3100792A1 (en) Methods and compositions for treatment of alzheimer's disease
Meier et al. The future of angiotensin II inhibition in cardiovascular medicine
WO2005011727A1 (en) Combination of an activator of soluble guanylate cyclase and an ace-inhibitor for the treatment of a cardiovascular or metabolic disorder
CA2749534A1 (en) Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia
Alpert et al. Additional antianginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta blocker for chronic stable angina pectoris
US20050059660A1 (en) Novel combination
Lefrandt et al. D078: Improved short-term blood pressure control by treatment with calcium antagonists in patients with mild to moderate hypertension.
Herrick et al. Drug therapy
US20250195519A1 (en) Combination of dasatinib and lovastatin for use in methods for the treatment of cardiac fibrosis
KR20050016452A (ko) Ｄｐｐ ⅳ 억제제와 심혈관계 화합물의 조합물
Bendersky et al. Comparison of amlodipine and enalapril in the treatment of isolated systolic hypertension in the elderly: an open-label, randomized, parallel-group study
MXPA04001174A (es) Tratamiento para lipodistrofia.
GR20160100618A (el) Συνδυασμος παρστατινης 1-26 και εξενατιδης

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)